Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Cellular Goods highlights recent developments and milestones for its 'Look Better' skincare range

Cellular Goods PLC

Cellular Goods PLC (LSE:CBX) chairman and interim CEO Darcy Taylor takes Proactive's Stephen Gunnion through the latest developments in the company's wellness business. Taylor highlighted the recent launch of their wellness division in several European countries, including France, Germany, Austria, Italy, Portugal, and Spain. This expansion aligns with their strategy to enter cannabigerol (CBG) friendly markets with high consumer demand and promising return on investment. The company's aim is to increase accessibility to its 'Look Better' skin range and enhance geographic distribution. Taylor also mentioned Cellular Goods' successful launch on the Sephora UK marketplace back in May, emphasizing the significance of the company's participation in promotional campaigns to increase product awareness. As the first CBD skincare brand in Sephora's offerings, these campaigns have been pivotal in expanding their customer base and leveraging their brand. Additionally, Taylor discussed the inclusion of their rejuvenating face serum in Jamie Greenberg's highly-anticipated 'swag bag', a significant endorsement from the renowned makeup artist. This has helped boost their presence and customer traction in the US market. Another strategic partnership highlighted is with Chill.com, a wellness product platform in the UK and the US. This collaboration aims to enhance the company's profile and sales in these regions, positioning Cellular Goods as a leading skincare brand on the platform. Looking ahead, Taylor expressed plans to continue expanding the 'Look Better' skincare range into new markets, focusing on revenue growth and increasing visibility among new and existing customers. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 27, 2023 06:53 AM Eastern Standard Time

Video

Women and Alzheimer’s Disease Subject of Giving Tuesday Webinar

Alzheimer’s Disease Research Foundation

Cure Alzheimer’s Fund will host Dr. Liisa Galea for a Giving Tuesday webinar on her research into women and Alzheimer’s disease. In this pre-recorded webinar, Dr. Galea presents her research on sex-based differences into the causes of Alzheimer's disease and discusses her findings with Meg Smith, CEO of Cure Alzheimer's Fund. Dr. Liisa Galea is the Treliving Family Chair in Women’s Mental Health at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada and a Professor of Psychiatry at the University of Toronto. Dr. Galea is a world-renowned expert in sex hormone influences on brain and behavior, with a focus on dementia and stress-related psychiatric disorders. Her research examines the intersection of hormones, and stress on brain plasticity in males and females. “Women develop Alzheimer's disease at twice the rate of men. Dr. Galea’s research into why women are more susceptible to Alzheimer’s and what is driving increased risk is impressive,” said CEO Smith. “She is a tireless advocate for women’s health research and for sex and gender-based analysis to improve cognitive aging for both women and men. We are lucky to hear from her.” “There is a lot of talk about precision medicine, the idea that we can tailor treatments based on our genes. But we rarely talk about how different treatments might be needed to combat neurodegenerative diseases like Alzheimer’s based on our sex,” said Galea. “The top three risk factors for late onset sporadic Alzheimer’s disease include APOE4 genotype and female sex. If you are an APOE4 carrier and a female you have an even greater risk of developing Alzheimer’s disease than if you are male carrier. Why not harness this information to see whether we can discover new therapies to combat this devastating illness. It’s time we figured out how sex plays a role, not only in the risk and progression of Alzheimer’s disease, but whether or not, different treatments may need to be tailored by sex.” For more information and to view the webinar, please visit Cure Alzheimer’s Fund at CureAlz.org and https://bit.ly/49jqQuO for the webinar. The webinar takes place during Alzheimer’s Awareness Month in November. It is estimated that more than 6.5 million Americans are currently living with Alzheimer’s disease two-thirds of those who are afflicted are women. It is projected that the share of adults 65 and older in the US population will rise to 22 percent by 2050. With age as the biggest risk factor, Alzheimer’s disease is poised to place an unmanageable financial burden on the US healthcare system, caregivers, and loved ones. About Cure Alzheimer’s Fund Cure Alzheimer’s Fund is a non-profit dedicated to funding the most promising research to prevent, slow, or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100 percent of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, visit https://www.curealz.org/. To learn about our the impact of Alzheimer’s on women and women working towards a cure, visit https://womenandalzheimers.org. Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website https://www.CureAlz.org

November 27, 2023 05:01 AM Eastern Standard Time

Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn

Oxford Cannabinoid Technologies Holdings PLC

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) CEO Clarissa Sowemimo Coker and CMO Dr Tim Corn speak to Thomas Warner from Proactive after the pharmaceutical group announced the appoint of Corn to its board of directors. The move follows his appointment as Chief Medical Officer in June 2023. Sowemimo-Coker highlights the importance of having a clinician on the board of a biopharmaceutical company. The appointment follows the successful announcement of Phase I single ascending dose results in October, reflecting OCT's commitment to addressing unmet medical needs with novel therapeutic approaches. Dr. Corn cites the combination of addressing unmet medical needs and the use of a novel cannabinoid approach as key factors that have attracted him to the business. He outlines his dual focus in the role, continuing as CMO to ensure efficient clinical programs aligned with regulatory requirements and bringing a physician's perspective to the board. He suggests that his expertise in clinical development and board work positions him well to balance patient interests and financial considerations. Discussing the company's cash runway, Sowemimo-Coker says the company is funded into April 2024. She assures stakeholders that the board is actively exploring various funding options, and updates will be provided as progress unfolds. While the details remain confidential, she hints at potential updates before the end of the year. The interview showcased OCT's commitment to advancing cannabinoid-based therapies, building a strong leadership team, and maintaining transparency in financial matters. Stakeholders are eagerly anticipating further developments as OCT continues its journey towards clinical and financial success. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

November 20, 2023 10:24 AM Eastern Standard Time

Video

News Release

MTL Cannabis road to success is based on flower first philosophy

MTL Cannabis

MTL Cannabis CEO Mike Perron joined Steve Darling from Proactive to to discuss the ethos and operations of their family-founded company, which places a high value on the quality and potential of the cannabis plant. The company's focus is primarily on flower-based products, including dry flower and pre-rolls. However, Perron notes that they are also venturing into hash production, leveraging their in-house knowledge and capabilities to broaden their product portfolio. Perron highlighted to Proactive the significant growth MTL Cannabis has experienced, attributing it to organic business development strategies. Remarkably, until January last year, the company's sales efforts were spearheaded by a single, highly dedicated sales representative. This individual not only worked with provincial boards but also took personal initiatives to promote the brand to dispensaries and budtenders during weekends. Furthermore, Perron provided insights into MTL Cannabis’s agreement with Canada House Wellness Group, a company deeply rooted in clinics and medical cannabis, originally established by veterans for veterans. The veteran community constitutes a crucial segment of their business, accounting for about 96% of their medical cannabis sales. Canada House operates 12 clinics across the country, including virtual ones, with a strategic presence near military bases to best serve the veteran population. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 17, 2023 01:44 PM Eastern Standard Time

Video

Navigating Open Enrollment

YourUpdateTV

Open Enrollment season is underway, and as we look ahead to 2024, now is the time to assess health care coverage options and select the plan that is best for you and your budget. Recently, Rhonda Randall, the Chief Medical Officer of UnitedHealthcare Employer and Individual participated in a nationwide satellite media tour to share tips for navigating the Open Enrollment season. A video accompanying this announcement is available at: https://youtu.be/mhpkMs2vBGk Enrollment periods aren’t the same for everyone, so there are key dates to keep in mind depending on your circumstances. Many employers set aside a 2- to 3-week period between September and December when employees can select health benefits for the following year. But just as millions of Americans prepare to choose health insurance for next year, a recent survey revealed that 1 in 3 people (36%) spend less than 1 hour reviewing their benefits options. For most people, not making an enrollment decision means you may be locked into your current plan for the upcoming year. If anything has changed this year – either with your current plan, health status or budget – that decision to do nothing could lead to unpleasant surprises or missed cost-savings in 2024. Because everyone has unique health and budget needs, and there is no one-size-fits-all approach to selecting a health plan, it’s important to stay informed before making these decisions. When choosing a health plan, here are a handful of tips that will hopefully lead to better health and cost savings: Take your time and consider all of your options Learn the language Help prevent financial surprises Check for mental health coverage Don’t forget about specialty benefits Look into wellness programs Explore virtual care services Visit UHCOpenEnrollment.com for tips, resources and information on plans in your area About Rhonda Randall Rhonda L. Randall, D.O., is the Chief Medical Officer of UnitedHealthcare Employer & Individual, the nation’s largest business serving the health coverage and well-being needs of nearly 28 million Americans. Dr. Randall collaborates with U.S. employers who are looking for quality, cost-effective, long-term solutions to health benefits for their employees and retirees. She also leads the clinical strategy development for these businesses to improve quality outcomes, ensure affordability and improve health and well-being. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 16, 2023 11:00 AM Eastern Standard Time

Video

News Release

Gattaca CEO focused on "rebuilding the business in a really sustainable way"

Gattaca PLC

Gattaca PLC CEO Matthew Wragg speaks to Thomas Warner from Proactive about how the STEM-focused talent solutions company has been performing during a challenging period in the market. Wragg discusses the final results for the year ending in July, highlighting a profit before tax of £2.6 million which marginally exceeded expectations. This positive trajectory comes within the context of a sluggish market, especially in permanent placements, which experienced a slowdown. He expresses optimism about Gattaca's direction, emphasising the internal changes and improvements made over the last 18 months. He noted that the company's focus on STEM skills helps add to its resilience. The conversation also touched on Gattaca's recent decision to relaunch its share buyback. Wragg outlined the rationale behind the move, citing a healthy cash position. Looking ahead, Wragg emphasises the importance of rebuilding corporate memory and fostering a positive environment for success and says he's focused on "rebuilding the business in a really sustainable way." Contact Details Proactive Investors +44 20 7989 0813 uk@proactiveinvestors.com

November 16, 2023 06:20 AM Eastern Standard Time

Video

Cure Alzheimer’s Fund Launches WomenandAlzheimers.org

Alzheimer’s Disease Research Foundation

In honor of National Alzheimer’s Disease Awareness Month, Cure Alzheimer’s Fund announces the launch of WomenandAlzheimers.org, a website dedicated to bringing awareness to the impact of Alzheimer’s on women, providing information on research into understanding sex-based differences and recognizing many of the women who are working toward finding a cure. There are more than 6 million people in the United States—and 50 million people throughout the world—currently living with an Alzheimer’s diagnosis, and experts estimate there may be as many as three times more people living with the disease who have not yet been diagnosed. Both men and women develop Alzheimer’s disease, but two-thirds of all patients are women, and women are frequently the primary caregivers for spouses, partners, parents and others with the disease. “For far too long, science has had a partial view into disease biology because only one sex was included in research studies,” said Meg Smith, CEO of Cure Alzheimer’s Fund. “Cure Alzheimer’s Fund has long required researchers to include consideration of potential sex differences in their projects. Understanding why and how Alzheimer’s develops differently in men and women, and the factors that increase resilience or risk, will lead to benefits for all Alzheimer’s patients.” WomenandAlzheimers.org is a resource to learn more about Alzheimer’s disease pathology, signs and symptoms, and the scientific discoveries that are advancing our understanding of the disease. Users can learn about ways to improve brain health, at any age, and read about the women who are working to find a cure, including researchers, Board members, staff members and advocates. About Cure Alzheimer’s FundCure Alzheimer’s Fund is a nonprofit dedicated to funding the most promising research to prevent, slow or reverse Alzheimer’s disease. Since its founding in 2004, Cure Alzheimer’s Fund has provided grants to the world’s leading researchers and contributed more than $180 million to research. Its funded initiatives have been responsible for many key breakthroughs in understanding the causes and pathology of Alzheimer’s disease. Cure Alzheimer’s Fund has received a 4-star rating for more than 12 consecutive years from Charity Navigator. With 100% of funds raised going to support research, Cure Alzheimer’s Fund has been able to provide grants to many of the best scientific minds in the field of Alzheimer’s research. For more information, visit https://WomenandAlzheimers.org and https://www.CureAlz.org/ Contact Details Barbara Chambers +1 978-417-9890 bchambers@curealz.org Company Website https://WomenandAlzheimers.org

November 15, 2023 05:46 AM Eastern Standard Time

News Release

Nevis Brands announces company is expanding into Michigan with signature brand Major

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to share significant news regarding the company's expansion into Michigan, marking its eighth state in the cannabis market. Nevis Brands has secured an exclusive agreement with Emerald Canning Partners to produce and distribute Major products in the state of Michigan, subject to approval by the Michigan Cannabis Regulatory Agency. Michigan is a strategically important market for Nevis Brands, as it witnessed cannabis sales totaling $2.3 billion in 2022, and it is expected to exceed the $3 billion mark in 2023. This makes Michigan the second territory in the Eastern United States where Nevis is establishing a licensee. Under the agreement with Emerald Canning Partners, Nevis Brands will have exclusive rights to produce and distribute all five flavors of Major, including Sunset Pink Lemonade, Pacific Blue Raspberry, Sacred Grape, Volcanic Orange Mango, and Passionfruit. Major is a dosable 100mg THC beverage known for delivering the effects of cannabis within 10-20 minutes of consumption. This expansion into Michigan represents a significant step for Nevis Brands as it continues to grow its presence in the rapidly evolving cannabis market. With its innovative Major product line and strategic partnerships, Nevis is well-positioned to capitalize on the increasing demand for cannabis products and provide consumers with unique and high-quality options. Contact Details Proactive Canada +1 604-688-8158 na-editorial@proactiveinvestors.com

November 14, 2023 01:49 PM Eastern Standard Time

Video

Health History on the Menu: This Thanksgiving Pass the Pumpkin Pie--and Grandma’s Health History

YourUpdateTV

Thanksgiving is a day filled with food, football, and conversations with family. While loved ones spend time together safely this Thanksgiving, they should consider talking about family health history. Recently, Susan Manley, senior vice president of Medical Services at Myriad Genetics and Ashley Dedmon, breast cancer previvor conducted a satellite media tour to talk about the importance of initiating health conversations at your holiday gathering. A video accompanying this announcement is available at: https://youtu.be/j0VMnkq1ij4 More than half (55%) of respondents to a recent Myriad Genetics Cancer Risk survey of women said that it’s important to know their cancer risk for “peace of mind.” Yet, 20% of women say they don’t talk about health issues in their family. This has potentially life-threatening consequences. Patients with a family history of breast, ovarian, uterine, or colorectal cancer may have a higher risk for developing these cancers. Getting answers to these questions may qualify your viewers for genetic hereditary cancer testing, which can help people and their clinician determine if they are at an increased risk of developing specific types of cancer. November is Family Health History Month. Encourage your audience to talk about family health history – it may save some lives. Myriad Genetics has an easy-to-complete family health history form to help start the conversation and take notes. During the holiday season, people can bring this form along to family gatherings and complete it by asking as many blood relatives, parents and grandparents, aunts and uncles, sisters and brothers about their family history. To learn more visit: myriad.com/KNOWYOURHISTORY BIOS Susan Manley, MS, MBA Senior Vice President, Medical Services Myriad Genetics, Inc. Salt Lake City, Utah Susan received her undergraduate degree in Biological Sciences from the University of Wisconsin-Milwaukee with a certification in biotechnology, her Master’s degree in Genetic Counseling from the University of Cincinnati, and her MBA from Loyola University in Maryland. She is an American Board of Genetic Counseling certified Genetic Counselor and holds a Genetic Counselor license in the state of Utah. She has been employed at Myriad Genetics for the past 28 years in both medical support and commercialization capacities and has been involved in the development of the commercial genetic testing market from medical, ethical, clinical, counseling, sales and marketing standpoints. Currently, she oversees a large staff of licensed genetic counselors who provide professional customer support and patient education for Myriad’s hereditary cancer and prenatal products. She is published in the medical literature including JAMA, JCO and Breast Cancer Research and Treatment. This combination of clinical knowledge and commercialization experience is unique and valuable in precision medicine space. Ashley Dedmon Breast cancer has impacted Ashley Demon’s family since before she was born - three generations of women in her family have been impacted by this disease. Ashley’s great grandmother, grandmother and mother all passed away from breast cancer, Ashley’s mother at only 42, when Ashley was 21. Cancer didn't stop there: her father was diagnosed with prostate cancer. Ashley’s hereditary mutations heightened her cancer risk. After taking the MyRisk® Hereditary Cancer Test, she learned she carried the BRCA2 gene mutation, putting her at an elevated risk for breast, ovarian and other cancers. After her first daughter had successfully weaned from breastfeeding, Ashley consulted with her doctors and came to the decision to have a prophylactic mastectomy, a procedure which could significantly reduce her risk of developing breast cancer. Since then, Ashley’s been living a normal life and has since given birth to a second daughter. Ashley’s doctors continue to actively monitor her health. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 14, 2023 10:00 AM Eastern Standard Time

Video

1 ... 30 31 32 33 34 ... 172